NCT05672836招募中4 期
A Randomized, Double-Blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, Enavogliflozin Compared to Placebo on Reducing Major Cardiovascular Events or Worsening Heart Failure in Patients With Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement (TAVR) and With Heart Failure With Preserved Ejection Fraction (HFpEF)
Duk-Woo Park, MD55 个研究点 分布在 1 个国家目标入组 1,040 人开始时间: 2024年12月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,040
- 试验地点
- 55
- 主要终点
- Time from randomization to first occurrence of a composite of major adverse cardiovascular events* or hospitalization for heart failure
研究概览
简要总结
The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events and Heart Failure events (hospitalization for Heart Failure or urgent Heart Failure visit) among patients who underwent transcatheter aortic valve replacement for severe aortic stenosis and with heart failure with preserved ejection fraction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Patients aged ≥19 with symptomatic aortic stenosis who underwent successful transcatheter aortic valve replacement (TAVR)* (either native valve or valve in valve with any approved/marketed device).
- •* A successful TAVI is defined as device success according to the VARC-2(Valve Academic Research Consortium 2) and VARC-3 criteria:
- •correct positioning of a single prosthetic heart valve into the proper anatomical location AND
- •intended performance of the prosthetic heart valve (mean aortic valve gradient <20 mmHg, peak velocity <3 m/s, no moderate or severe prosthetic valve regurgitation) AND
- •absence of periprocedural complications (any type of stroke, life-threatening bleeding, acute coronary artery obstruction requiring intervention, major vascular complication requiring intervention, unresolved acute valve thrombosis, or any requirement of a repeat procedure).
- •2. Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- •Left ventricular ejection fraction (LVEF) ≥40%
- •structural heart disease_Left ventricular hypertrophy (LVH) or Left atrial enlargement
- •A. Left ventricular hypertrophy (LVH) with septal thickness or posterior wall thickness ≥ 1.1 cm or
- •B. Left atrial (LA) enlargement with at least one of the following: LA width (diameter) ≥3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20cm2, or LA volume ≥ 55mL or LA volume index ≥ 29mL/m.
- •NT-proBNP ≥ 300 pg/mL (for patients without ongoing atrial fibrillation) or NT-proBNP must be ≥ 600 pg/mL (for patients with ongoing atrial fibrillation).
- •3. Patients who voluntarily participated in the written agreement
排除标准
- •Acute decompensated Heart Failure (exacerbation of chronic Heart Failure) requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support, or hemodynamic instability following the transcatheter aortic valve replacement procedure.
- •Currently receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomization; discontinuation of current use of SGLT2 inhibitor for the purposes of study enrolment is not permitted.
- •Known allergy, hypersensitivity, or previous intolerance to an SGLT2 inhibitors.
- •HF with reduced ejection fraction (LVEF <40%).
- •Type 1 diabetes mellitus or diabetes ketoacidosis.
- •Chronic cystitis and/or recurrent urinary tract infection (≥2 times within 1 year).
- •Stroke or transient ischemic attack within 12 weeks prior to enrollment.
- •Symptomatic persistent hypotension and/or a systolic blood pressure (SBP) < 95 mm Hg at screening or at randomization.
- •SBP ≥180 mmHg irrespective of treatment or SBP ≥160 mmHg with at least ≥3 antihypertensive drugs at screening or randomization.
- •Heart failure due to any of the following causes; known infiltrative cardiomyopathy (e.g. amyloid, sarcoid, lymphoma, endomyocardial fibrosis, haemochromatosis, Fabry disease), active myocarditis, constrictive pericarditis, cardiac tamponade, known hypertrophic obstructive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD), or uncorrected primary valvular disease.
- •Severe renal insufficiency (eGFR <30 ml/min/1.73 m2 of body-surface area based on the Modification of Diet in Renal Disease (MDRD) formula) or end-stage renal disease or requiring dialysis at the time of screening.
- •Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices, coagulopathy) or serum levels of transminases or alkaline phosphatase more than two times the upper limit of normal at screening.
- •Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension.
- •Current or suspicious malignancy or history of malignancy within 5 years
- •Uncontrolled anaemia or haemoglobin <9g/dl
- •Uncontrolled hypothyroidism or arrhythmia or tachycardia
- •Current ongoing alcoholic or drug addict
- •Subjects with non-cardiac co-morbidities with life expectancy less than 12 months
- •Planned major high-risk operation after transcatheter aortic valve replacement (TAVR)
- •Women of childbearing age who have not reached a consensus on the use of highly effective contraception. Pregnancy or breastfeeding.
- •Participation in other clinical trials, However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;
- •Participating in the observational study expected no effect on the safety and/or effectiveness evaluation of this trial.
- •Screening failed before any interventional factor is involved.
- •Participants who have completed their involvement in clinical trials and have surpassed a 4-week period since their last administration of the investigational drug.
- •Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.
研究组 & 干预措施
Enavogliflozin Group
Experimental
0.3 mg 1 tablet once daily
干预措施: Enavogliflozin (Drug)
placebo as add-on to standard of care treatment group
Placebo Comparator
Placebo matching enavogliflozin
干预措施: Standard-of-Care (Drug)
结局指标
主要结局
Time from randomization to first occurrence of a composite of major adverse cardiovascular events* or hospitalization for heart failure
时间窗: 12 months
Time from randomization to the first occurrence of a composite of major adverse cardiovascular events\* or hospitalization for heart failure at 12 months after randomization. \*Major adverse cardiovascular events included death from any causes, nonfatal myocardial infarction, or nonfatal stroke. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.
次要结局
- Event rate of nonfatal stroke(12 months)
- Event rate of Composite renal endpoint(12 months)
- Event rate of Rehospitalization for any reason(12 months)
- Changes in measures of cardiac volume and function assessed by serial echocardiography(12 months)
- Changes in New York Heart Association (NYHA) functional class and the Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score(12 months)
- Serial change in NT-proBNP(12 months)
- Event rate of death from any cause(12 months)
- Event rate of hospitalization for heart failure(12 months)
- Event rate of nonfatal myocardial infarction(12 months)
- Event rate of the safety events(12 months)
研究者
Duk-Woo Park, MD
Professor, Cardiology, Asan Medical Center Heart Institute, Valvular Heart Disease Center, Ischemic Heart Disease Center
Asan Medical Center
研究点 (55)
Loading locations...
相似试验
已完成
3 期
Effect of Ertugliflozin on Cardiac Function in DiabetesType2 DiabetesHeart FailureNCT03717194Soo Lim102
已完成
3 期
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)Heart FailureNCT03057977Boehringer Ingelheim3,730
招募中
3 期
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AFChronic Coronary SyndromeAtrial FibrillationNCT05852704Region Örebro County800
已完成
3 期
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and HypertensionHypertensionDiabetes Mellitus, Type 2NCT02182830Boehringer Ingelheim166
已完成
3 期
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure SymptomsHeart FailureNCT03448419Boehringer Ingelheim312